|
Real-time Estimate
Cboe Europe
12:45:36 18/11/2026 +04
|
5-day change | 1st Jan Change | ||
| 1.727 SEK | -0.29% |
|
-2.16% | -64.16% |
| 11-09 | Oncopeptides Wins EU Approval to Expand Pepaxti Label for Third-line Treatment | MT |
| 11-09 | Oncopeptides receives EU approval for expanded use of Pepaxti | FW |
| Market Cap | 685M 67.75M 61.51M 56.82M 51.26M 96.77M 6.33B 100M 271M 3.42B 254M 249M 10.79B | P/E 2026 * |
-3.77x | P/E 2027 * | -7.7x |
|---|---|---|---|---|---|
| Enterprise Value | 751M 74.29M 67.44M 62.29M 56.2M 106M 6.94B 110M 297M 3.75B 279M 273M 11.83B | EV / Sales 2026 * |
6.12x | EV / Sales 2027 * | 3.21x |
| Free-Float |
96.15% | Yield 2026 * |
-
| Yield 2027 * | - |
| Markets | Quality | ||
|---|---|---|---|
Nasdaq Stockholm
| ONCO | Delayed | |
| ONCOs | Real-time | ||
| OND | Delayed | ||
| 0RN4 | Delayed | ||
| 0RN4 | Real-time | ||
| OND | Delayed | ||
| OND | Real-time |
Last Transcript: Oncopeptides AB
| 11-12 | Oncopeptides : November 12, 2026 | PU |
| 11-09 | Oncopeptides : November 9, 2026 | PU |
| 11-05 | Oncopeptides : November 5, 2026 | PU |
| 11-04 | Oncopeptides : November 4, 2026 | PU |
| 10-30 | Oncopeptides : Number of shares and votes in Oncopeptides | PU |
| 1 day | -0.29% | ||
| 1 week | -2.16% | ||
| Current month | +2.93% | ||
| 1 month | -0.92% | ||
| 3 months | +1.35% | ||
| 6 months | +0.58% | ||
| Current year | -64.16% |
| 1 week | 1.7 | 1.82 | |
| 1 month | 1.62 | 1.88 | |
| Current year | 1.26 | 4.91 | |
| 1 year | 1.26 | 5.8 | |
| 3 years | 1.1 | 9.4 | |
| 5 years | 1.1 | 50.84 | |
| 10 years | 1.1 | 215 |
| Manager | Title | Age | Since |
|---|---|---|---|
Sofia Heigis
CEO | Chief Executive Officer | 46 | 07/08/2023 |
| Director of Finance/CFO | 52 | 13/11/2023 | |
Stefan Norin
CTO | Chief Tech/Sci/R&D Officer | 54 | 01/09/2023 |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 65 | 01/01/2012 | |
| Director/Board Member | 63 | 01/02/2017 | |
Per Wold-Olsen
CHM | Chairman | 79 | 17/05/2018 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 20/03/26 | Free | Chief Technology Officer | 3,000 | 0.0008% | ||
| 18/03/26 | Buy | 14,631 | 0.0038% | |||
| 17/03/26 | Free | Investor Relations Manager | 66 | 0.0000% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -0.29% | -2.16% | -66.24% | -80.25% | 67.75M | ||
| +1.15% | -2.81% | +55.79% | +71.12% | 66.37B | ||
| +0.96% | -1.51% | +9.33% | +91.30% | 58.86B | ||
| +0.81% | +0.42% | +25.93% | +86.56% | 55.22B | ||
| +0.48% | -2.53% | +9.73% | +121.14% | 47.21B | ||
| -2.69% | -6.38% | +19.19% | +25.79% | 42.45B | ||
| -0.70% | +4.93% | +17.77% | +45.03% | 36.44B | ||
| -2.50% | -15.73% | +135.31% | +662.73% | 35.19B | ||
| -0.23% | -2.11% | +81.94% | +57.03% | 32.66B | ||
| -0.83% | +1.98% | -38.27% | +390.98% | 26.73B | ||
| Average | -0.40% | -2.31% | +25.05% | +147.14% | 40B | |
| Weighted average by Cap. | -0.16% | -2.18% | +34.93% | +146.95% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 123M 12.14M 11.02M 10.18M 9.18M 17.34M 1.13B 18M 48.51M 612M 45.54M 44.58M 1.93B | 234M 23.2M 21.06M 19.46M 17.55M 33.13M 2.17B 34.4M 92.72M 1.17B 87.04M 85.21M 3.7B |
| Net income | -176M -17.41M -15.81M -14.6M -13.17M -24.87M -1.63B -25.82M -69.59M -878M -65.33M -63.95M -2.77B | -107M -10.57M -9.59M -8.86M -8M -15.1M -987M -15.67M -42.24M -533M -39.65M -38.82M -1.68B |
| Net Debt | 66M 6.53M 5.93M 5.48M 4.94M 9.33M 610M 9.69M 26.1M 329M 24.51M 23.99M 1.04B | 68M 6.73M 6.11M 5.64M 5.09M 9.61M 629M 9.98M 26.9M 339M 25.25M 24.72M 1.07B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 18/11/26 | SEK 1.724 | -0.46% | 48,777 |
| 17/11/26 | SEK 1.732 | -2.20% | 2,045,543 |
| 16/11/26 | SEK 1.771 | +0.06% | 1,322,372 |
| 13/11/26 | SEK 1.770 | +1.14% | 3,247,293 |
| 12/11/26 | SEK 1.750 | -0.57% | 2,284,702 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
- Stock Market
- Stocks
- ONCO Stock
Select your edition
All financial news and data tailored to specific country editions
















